ModernMedicine Resource Center More Topics

Video

Sulcus-to-sulcus suture technique offers solution for silicone oil use in aphakic eyes with iris loss

Retention sutures placed sulcus-to-sulcus in the iris plane are effective for keeping the silicone oil out of the anterior chamber.

Retina Treatments

Outer retinal layer thickness predicts visual acuity in diabetic macular oedemaDiabetes mellitus is a common health problem in developed countries, with diabetic macular oedema (DMO) being a major cause of visual loss. A variety of treatment modalities for DMO are available including laser, steroid and intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents.
Do more anti-VEGF injections lead to better clinical outcomes?The appropriate use of agents that inhibit vascular endothelial growth factor (VEGF) can bring significant improvements to both short-term and long-term visual acuity for patients with neovascular AMD.
How to avoid explosive silicone oil injector separationEnsuring correct alignment between the syringe and the cap during silicone oil injection can prevent complications during vitrectomy, said Jay M. Stewart, MD, (San Francisco) presenting during the Retina Subspecialty Day of the 2015 American Academy of Ophthalmology meeting.
DME trials show advantage to early aflibercept treatment
DME trials show advantage to early aflibercept treatmentPatients treated early with aflibercept (Eylea, Regeneron Pharmaceuticals) for diabetic macular edema (DME) gain more visual acuity than those treated later in the course of the disease.
Innovations fuel sustained drug-delivery methods for AMD
Innovations fuel sustained drug-delivery methods for AMDA variety of newer drug delivery approaches may change how patients with age-related macular degeneration are treated.
Study: Fluocinolone acetonide 0.2 µg/day reduced DR progressionTreatment with fluocinolone acetonide 0.2 µg/day significantly reduced progression to proliferative diabetic retinopathy (PDR) in patients who were part of the FAME trials1,2 and had visual acuity loss due to diabetic macular edema (DME), according to Charles C. Wykoff, MD, PhD.
The AAO's preferred practice patterns for AMDHigh-level evidence supports the use of anti-vascular endothelial growth factor (VEGF) therapy for neovascular age-related macular degeneration (AMD), but falls short of recommending any one agent over another in terms of efficacy or safety, said Paul Sternberg Jr., MD.
Lesion size plays key role in squalamine eye drops therapySqualamine lactate—when combined with ranibizumab for treating neovascular age-related macular degeneration—achieved improved visual function when compared with the results achieved with ranibizumab treatment alone.
Surgical gene therapy study for wet AMD yields mixed resultsIn a phase IIa study of patients with neovascular age-related macular degeneration, a single subretinal injection of rAAV.sFlt-1 gene therapy demonstrated acceptable safety, but not a complete or durable anti-VEGF response. Additional preclinical research is under way.
Steroids may be preferable to anti-VEGF for DME in certain casesTwo-year study results highlight some advantages of steroid treatment for DME.